AMRXAmneal Pharmaceuticals, Inc.

Healthcare

$19.92+103% 1Y

$19.92

$9.6052 weeks$20.49

Is the price fair?

Fair

Neither cheap nor expensive: cheap vs its sector, but priced for +16% a year vs +10% a year delivered.

1 good, 1 to watch, 1 without data

What the price assumes~+16% a year

Priced for ~16% a year FCF growth. The price demands more than its three-year revenue growth of 10% a year, priced for acceleration.

Vs sector (EV/EBIT)17.8×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 81% of the market

FCF yieldbehind 81% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What AMRX's price assumes

Amneal Pharmaceuticals, Inc. trades at 40.6× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.

40.6

Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · 2.07× the median: the market pays up for this one

Price / sales: 1.77
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 2.3%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: +16%
Growth the price implies · The price pays for +16% free cash flow growth a year for a decade; the business has delivered −4.4% a year over the last three.